mitochondrial ribosomal protein L50 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored MRPL50P1 profile across patient tissues and cancer cell-line models. MRPL50P1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MRPL50P1 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, MRPL50P1 RNA expression shows 12,530 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where MRPL50P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL50P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL50P1 survival associations across molecular data types. MRPL50P1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL50P1 RNA expression–survival associations across cancer types. High MRPL50P1 expression shows unfavorable associations in MESO, LUAD, THYM, UCEC, SKCM and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MRPL50P1 RNA expression.
This table summarizes MRPL50P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MRPL50P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL50P1 shows higher tumor expression in KIRC. The KIRC box plot shows higher MRPL50P1 RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .019).
This table shows molecular features associated with MRPL50P1 in patient tissues and cancer cell lines. In patient samples, MRPL50P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
